Navigation Links
DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
Date:1/5/2013

New York, NY (PRWEB) January 05, 2013

The prescription drug resource center DrugRisk.com has updated its comprehensive database to include the latest warnings on Yaz side effects as well as legal news on the ongoing Yaz litigation and settlements.

“The goal of DrugRisk is to improve patient safety through education. This includes furnishing the latest warnings, recalls, studies and litigation news related to prescription drugs like Yaz and Yasmin used by millions of women,” explains DrugRisk representative Ryan Mayer.

The resource center is advising patients of the latest Yaz health warning, in which the American College of Obstetricians and Gynecologists cautioned that birth control pills containing drospirenone, such as Yaz and Yasmin, may have a higher risk of causing blood clots.*

DrugRisk also contains studies previously issued by the British Medical Journal and U.S. Food and Drug Administration which show drugs like Yaz can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.**

In legal news, DrugRisk has learned that thousands of Yaz lawsuits have been consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

According to the most recent financial report from Bayer, the company has settled approximately 3,500 of these Yaz claims, at a total cost of nearly $750 million, or around $214,000 per case.*** Bayer also confirmed they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

The Drug Risk Resource Center cautions victims who wish to learn about their legal options that they should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”
**British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
***Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012

Read the full story at http://www.prweb.com/releases/yaz-lawsuits/claims/prweb10290083.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Announces Updated Information on Mirena Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
4. Nutrisystem Announces Latest Weight Loss Success Story: Long Beach Husband and Wife Drop a Combined Total of 46 Pounds; Plus, Expert Dieting Tips for Couples
5. Greg Reid of Napoleon Hill Foundation Makes a Special World Premier Announcement of His Latest Project (The Secret of Happiness) on the “Your Do Over” Podcast on iTunes
6. Nutrisystem Announces Latest Weight Loss Success Story: Life-long Fad Dieter Shari West Finds the Key to Dropping Nearly 60 Pounds*
7. Vitamin D & Your Health Report Latest Release from MedSmart Members
8. Dr. Ilan Cohen Advises Caution with Latest Flurry of “No Cost” LASIK Screening Offers
9. Atlanta Plastic Surgeon Dr. David Whiteman Says Increased Popularity of Ethnic Rhinoplasty, Indicated by Latest ASPS Statistics, Emphasizes Need for Experienced Surgeons
10. Cavern Technologies Kansas City Data Center Continues Rapid Growth with Latest Data Center Expansion
11. Latest West Nile Tally: 5,245 Cases, 236 Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased to announce that California ... members. As part of the amalgam separator endorsement, all CDA members may purchase an ... off the retail value. This partnership between PureLife and CDA is especially timely as ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Ulster University, ... June, 2017 from 9 am to 3 pm to present to graduate students exciting ... is an original curriculum project led by The Health Improvement Service of the ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency ... throughout eastern Texas, is announcing the launch of a new charity drive to benefit ... in the United States reveal that an estimated 252, 710 new cases of invasive ...
(Date:6/22/2017)... , ... June 22, 2017 , ... Branches, Inc. has ... than $245,000 in grant funding to support its programs focused on providing opportunity to ... was awarded a grant by the Foundation of $15,000 to support its , Climb ...
(Date:6/22/2017)... ... ... Groove Ring is excited to announce they've partnered with Olympic runner Jared ... all-purpose rings. Whether you’re an athlete, adventurer, professional, or love to venture the great ... the rock face to the auto shop, Groove Ring is the world's first breathable ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology: